Cabio Biotech (Wuhan) Co (SHSE:688089) Long-Term Debt: ¥98.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688089 Cabio Biotech (Wuhan) Co Ltd SHSE:688089
75 GF Score
Price ¥8.36
GF Value ¥12.10
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Cabio Biotech (Wuhan) Co Long-Term Debt?

Cabio Biotech (Wuhan) Co SHSE:688089 +0.60% 75 Long-Term Debt is ¥98.8 Mil as of Jun. 2026. GuruFocus rates SHSE:688089 with a GF Score™ of 75/100 and a GF Value™ of ¥12.10 (Possible Value Trap). The stock has 9 warning signs investors should review.

Cabio Biotech (Wuhan) Co's Long-Term Debt for the quarter that ended in Jun. 2026 was ¥98.8 Mil.

Cabio Biotech (Wuhan) Co's quarterly Long-Term Debt increased from Dec. 2025 (¥49.5 Mil) to Mar. 2026 (¥106.4 Mil) but then declined from Mar. 2026 (¥106.4 Mil) to Jun. 2026 (¥98.8 Mil).

Cabio Biotech (Wuhan) Co's annual Long-Term Debt increased from Dec. 2023 (¥0.0 Mil) to Dec. 2024 (¥12.6 Mil) and increased from Dec. 2024 (¥12.6 Mil) to Dec. 2025 (¥49.5 Mil).

Cabio Biotech (Wuhan) Co  (SHSE:688089) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Cabio Biotech (Wuhan) Co Long-Term Debt Related Terms

Cabio Biotech (Wuhan) Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Cabio Biotech (Wuhan) Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cabio Biotech (Wuhan) Co Long-Term Debt Chart

Cabio Biotech (Wuhan) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 12.63 49.53

Cabio Biotech (Wuhan) Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.99 47.71 49.53 106.35 98.84
SHSE:688089
75GF Score
Cabio Biotech (Wuhan) Co Ltd SHSE:688089
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ¥98.8 Mil mean?
Cabio Biotech (Wuhan) Co (SHSE:688089) has a Long-Term Debt of ¥98.8 Mil as of Jun. 2026.
Is Cabio Biotech (Wuhan) Co's Long-Term Debt too high?
Cabio Biotech (Wuhan) Co's current Long-Term Debt is ¥98.8 Mil. Overall, Cabio Biotech (Wuhan) Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cabio Biotech (Wuhan) Co's Long-Term Debt compare to VRTX and REGN?
Cabio Biotech (Wuhan) Co's Long-Term Debt of ¥98.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Cabio Biotech (Wuhan) Co's current Long-Term Debt is ¥98.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabio Biotech (Wuhan) Co stock overvalued right now?
Based on GuruFocus' analysis, Cabio Biotech (Wuhan) Co (SHSE:688089) is currently considered Possible Value Trap. The stock's GF Value™ is ¥12.10, compared to a current price of ¥8.36 — trading 30.9% below its estimated fair value. The current Long-Term Debt is ¥98.8 Mil. Cabio Biotech (Wuhan) Co's overall GF Score™ is 75/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Cabio Biotech (Wuhan) Co (SHSE:688089), the current Long-Term Debt is ¥98.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cabio Biotech (Wuhan) Co (SHSE:688089) Overvalued in 2026?

Based on GuruFocus' analysis, Cabio Biotech (Wuhan) Co stock appears to be undervalued. The current stock price of ¥8.36 is trading 30.9% below its estimated GF Value™ of ¥12.10. GuruFocus considers Cabio Biotech (Wuhan) Co to be Possible Value Trap.

Key valuation signals for SHSE:688089:

  • Long-Term Debt: ¥98.8 Mil
  • GF Value™: ¥12.10 vs. price of ¥8.36 (30.9% below fair value)
  • GF Score™: 75/100 with 9 warning signs

No single metric tells the full story. See the SHSE:688089 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cabio Biotech (Wuhan) Co Business Description

Address No. 999, Gaoxin Avenue, East Lake New Technology Development Zone, Hubei Province, Wuhan, CHN, 430075
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
75GF Score

Get the complete analysis for SHSE:688089

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.36
Price
¥12.10
GF Value